Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

Dina Bassiouny; Nadia Ismiil; Valerie Dubé; Guangming Han; Matthew Cesari; Fang I. Lu; Elzbieta Slodkowska; Carlos Parra-Herran; Hak Fai Chiu; Magda Naeim; Nim Li; Mahmoud Khalifa; Sharon Nofech-Mozes

doi:10.1177/1066896917752861

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

Dina Bassiouny, Nadia Ismiil, Valerie Dubé, Guangming Han, Matthew Cesari, Fang I. Lu, Elzbieta Slodkowska, Carlos Parra-Herran, Hak Fai Chiu, Magda Naeim, Nim Li, Mahmoud Khalifa, Sharon Nofech-Mozes

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

Original language	English (US)
Pages (from-to)	306-317
Number of pages	12
Journal	International Journal of Surgical Pathology
Volume	26
Issue number	4
DOIs	https://doi.org/10.1177/1066896917752861
State	Published - Jun 1 2018
Externally published	Yes

Bibliographical note

Funding Information:
The authors thank the valuable technical support of Xu Guo (construction of tissue microarrays), Samira Alminawi (immunohistochemical testing), and Manar AL-Assi. ARID1A and PTEN immunohistochemistry were performed at the Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada. Dr. Cheng-Han Lee has performed part of the immunohistochemistry analysis. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.

Publisher Copyright:
© 2018, © The Author(s) 2018.

Keywords

HER2
HNF1b
PAX8
SATB2
immunohistochemistry
mucinous
napsin A
ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1177/1066896917752861

Cite this

Bassiouny, D., Ismiil, N., Dubé, V., Han, G., Cesari, M., Lu, F. I., Slodkowska, E., Parra-Herran, C., Chiu, H. F., Naeim, M., Li, N., Khalifa, M., & Nofech-Mozes, S. (2018). Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. International Journal of Surgical Pathology, 26(4), 306-317. https://doi.org/10.1177/1066896917752861

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. / Bassiouny, Dina; Ismiil, Nadia; Dubé, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang I.; Slodkowska, Elzbieta; Parra-Herran, Carlos; Chiu, Hak Fai; Naeim, Magda; Li, Nim; Khalifa, Mahmoud; Nofech-Mozes, Sharon.

In: International Journal of Surgical Pathology, Vol. 26, No. 4, 01.06.2018, p. 306-317.

Research output: Contribution to journal › Article › peer-review

Bassiouny, D, Ismiil, N, Dubé, V, Han, G, Cesari, M, Lu, FI, Slodkowska, E, Parra-Herran, C, Chiu, HF, Naeim, M, Li, N, Khalifa, M & Nofech-Mozes, S 2018, 'Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma', International Journal of Surgical Pathology, vol. 26, no. 4, pp. 306-317. https://doi.org/10.1177/1066896917752861

Bassiouny, Dina ; Ismiil, Nadia ; Dubé, Valerie ; Han, Guangming ; Cesari, Matthew ; Lu, Fang I. ; Slodkowska, Elzbieta ; Parra-Herran, Carlos ; Chiu, Hak Fai ; Naeim, Magda ; Li, Nim ; Khalifa, Mahmoud ; Nofech-Mozes, Sharon. / Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. In: International Journal of Surgical Pathology. 2018 ; Vol. 26, No. 4. pp. 306-317.

@article{e8621afbdde8411087c3228adb3df69b,

title = "Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma",

abstract = "The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.",

keywords = "HER2, HNF1b, PAX8, SATB2, immunohistochemistry, mucinous, napsin A, ovarian cancer",

author = "Dina Bassiouny and Nadia Ismiil and Valerie Dub{\'e} and Guangming Han and Matthew Cesari and Lu, {Fang I.} and Elzbieta Slodkowska and Carlos Parra-Herran and Chiu, {Hak Fai} and Magda Naeim and Nim Li and Mahmoud Khalifa and Sharon Nofech-Mozes",

note = "Funding Information: The authors thank the valuable technical support of Xu Guo (construction of tissue microarrays), Samira Alminawi (immunohistochemical testing), and Manar AL-Assi. ARID1A and PTEN immunohistochemistry were performed at the Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada. Dr. Cheng-Han Lee has performed part of the immunohistochemistry analysis. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} The Author(s) 2018.",

year = "2018",

month = jun,

day = "1",

doi = "10.1177/1066896917752861",

language = "English (US)",

volume = "26",

pages = "306--317",

journal = "International Journal of Surgical Pathology",

issn = "1066-8969",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

AU - Bassiouny, Dina

AU - Ismiil, Nadia

AU - Dubé, Valerie

AU - Han, Guangming

AU - Cesari, Matthew

AU - Lu, Fang I.

AU - Slodkowska, Elzbieta

AU - Parra-Herran, Carlos

AU - Chiu, Hak Fai

AU - Naeim, Magda

AU - Li, Nim

AU - Khalifa, Mahmoud

AU - Nofech-Mozes, Sharon

N1 - Funding Information: The authors thank the valuable technical support of Xu Guo (construction of tissue microarrays), Samira Alminawi (immunohistochemical testing), and Manar AL-Assi. ARID1A and PTEN immunohistochemistry were performed at the Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada. Dr. Cheng-Han Lee has performed part of the immunohistochemistry analysis. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. Publisher Copyright: © 2018, © The Author(s) 2018.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

AB - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

KW - HER2

KW - HNF1b

KW - PAX8

KW - SATB2

KW - immunohistochemistry

KW - mucinous

KW - napsin A

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85041922271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041922271&partnerID=8YFLogxK

U2 - 10.1177/1066896917752861

DO - 10.1177/1066896917752861

M3 - Article

C2 - 29338553

AN - SCOPUS:85041922271

VL - 26

SP - 306

EP - 317

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 4

ER -

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access

Other files and links

Fingerprint

Cite this